The tweet was deleted by the author.
But we saved everything 🙂.
Vir Biotechnology announced it has presented early Phase 1 clinical data for its candidate VIR-5500 targeting metastatic prostate cancer at ASCO2026.
The company also highlighted its strategic global collaboration with Astellas to advance the development of what it positions as a potential best-in-class therapeutic. These developments underscore Vir Biotechnology's growing focus on oncology partnerships and novel drug candidates in early-stage research.
View post on X Loading...
Vir Biotechnology previously shared new data at EASL2026 analyzing body mass index effects in chronic hepatitis delta patients from the Phase 2 SOLSTICE study. The company also reported Week 96 results showing continued HDV suppression in the same SOLSTICE Phase 2 trial. These studies reflect Vir’s established focus on antiviral therapy development.